International medical diagnostics company selects Translational Software’s evidence-based PGx content to broaden genetic testing services in Australia

July 10, 2018 09:00 AM Eastern Daylight Time


BELLEVUE, Wash.–(BUSINESS WIRE)–Translational Software®, Inc. (TSI), a global leader in the intelligent use of genetic data for clinical decision support, has finalized an agreement with Sonic Genetics, a member of Sonic Healthcare, one of the world’s largest medical diagnostics companies, to provide pharmacogenomic (PGx) decision support for lab testing services in Australia. PGx testing assesses an individual’s genomic markers to predict clinical response to specific medications to help clinicians more closely tailor personalized treatment.


Sonic Genetics chose to partner with TSI based on its robust knowledge-base of actively curated, evidence-based PGx content. TSI’s proprietary knowledge platform provides flexible reporting, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions to guide clinical decision-making and enable physicians to prescribe the most effective medications. With clinical reporting for 65 genes, TSI’s PGx platform can be tailored to a variety of clinical specialties including cardiovascular, psychiatric, pain, internal medicine and geriatrics. Most importantly, TSI’s platform is rigorously curated and continually updated to prevent alert fatigue by only surfacing information that has the highest levels of evidence.


read more